THC and CBD: What the Controlled Evidence Actually Separates

A source-grounded review of what controlled human evidence separates about THC and CBD, citing 5 authoritative sources.

By Cannible Editorial

2026-08-08

The clearest controlled human evidence separates THC from CBD in three ways: THC produced subjective intoxication and several acute behavioral and physiological effects in one oral comparison, while CBD did not differ from placebo on the measured outcomes in that study; vaporized THC-containing cannabis impaired early driving performance, whereas CBD-dominant cannabis did not significantly differ from placebo; and adding CBD to THC did not reliably prevent THC impairment, with some studies finding no protection and one finding dose- or ratio-dependent attenuation of specific psychotomimetic effects but not the subjective high. 1 2 3 4

This is general information, not individualized medical, dosing, driving, or legal advice. A personal decision about cannabis or a CBD medicine should be discussed with a clinician, pharmacist, or other qualified professional.

What each kind of evidence can tell us

The main evidence discussed here is controlled human evidence: randomized, blinded or placebo-controlled experiments in healthy volunteers or occasional cannabis users. These studies can compare short-term effects under specified conditions, but they do not establish that every person, product, dose, or route will produce the same result. 1 2 3 4

The approved-drug evidence is a different category from consumer-product evidence. It concerns controlled and uncontrolled trials of Epidiolex in patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, including pediatric and adult participants taking other antiseizure medicines. Findings from those trials should not be transferred automatically to nonprescription CBD products. 5

Intoxication and acute effects are not the same question

In a randomized, double-blind, placebo-controlled crossover study of 16 healthy men, a single oral 10-milligram dose of THC was associated with anxiety, dysphoria, positive psychotic symptoms, physical and mental sedation, subjective intoxication, and increased heart rate relative to both placebo and 600 milligrams of oral CBD. In that same study, CBD did not differ from placebo on the measured symptomatic or physiological variables. This is controlled human evidence about acute effects after one oral dose, not proof that CBD is universally non-intoxicating or universally well tolerated in every circumstance. 4

Intoxication means the subjective experience reported in that study, including feeling intoxicated; acute effects is the broader category that also includes anxiety, sedation, psychotic symptoms, and heart-rate changes. A separate human laboratory study tested CBD-to-THC ratios of 1:1, 2:1, and 3:1. The lowest CBD amount tested, 2.5 milligrams alongside THC at 0.035 milligrams per kilogram, produced the greatest attenuation of specific THC-induced psychotomimetic effects and a neural-noise measure. However, additional CBD did not reduce the subjective experience of the THC-induced high. Thus, a result involving one acute psychotomimetic outcome should not be described as elimination of intoxication. 3

CBD alongside THC: protection is not a general rule

In a randomized, double-blind, within-participant driving trial of 26 healthy occasional cannabis users, vaporized THC-dominant cannabis and THC/CBD-equivalent cannabis significantly increased lane weaving compared with placebo during testing 40 to 100 minutes after consumption. CBD-dominant cannabis did not significantly differ from placebo at that time. At 240 to 300 minutes, none of the THC, CBD, or THC/CBD conditions differed significantly from placebo on the lane-weaving measure. The investigators also cautioned that the CBD-dominant result could not exclude clinically important impairment and that the tested doses might not represent common use. 1

A separate controlled human study used vaporized cannabis containing 125 milligrams of material: THC-dominant cannabis contained 11% THC and less than 1% CBD, while the THC/CBD-equivalent preparation contained 11% THC and 11% CBD. Both active preparations increased lane weaving and impaired performance on several cognitive tasks. The THC/CBD-equivalent preparation was no less impairing than the THC-dominant preparation, and impairment on two tasks was worse with the equivalent preparation. Peak plasma THC was also higher after the THC/CBD-equivalent preparation, suggesting a possible interaction affecting exposure. This is evidence about those tested vaporized preparations and dose conditions, not every THC-to-CBD combination. 2

Product composition, route, and dose change the question

Product composition refers to what the preparation contained: THC-dominant, CBD-dominant, or THC/CBD-equivalent cannabis. Route of administration refers to how it was taken: the driving and cognition studies used vaporization, while the direct THC-versus-CBD comparison used oral administration. Dose refers to the amount administered: the oral comparison used 10 milligrams of THC or 600 milligrams of CBD, the ratio study used 2.5 milligrams of CBD with THC at 0.035 milligrams per kilogram in its lowest-CBD condition, and the vaporized cognition study used 125 milligrams of cannabis material with the stated cannabinoid percentages. 1 2 3 4

Those distinctions matter because a finding after oral CBD cannot be assumed to describe vaporized CBD, and a finding with CBD added to THC cannot be assumed to describe CBD alone. The driving trial itself reported that its tested doses might not represent common usage. The evidence supplied here does not establish a universal conversion between oral and vaporized products, a universal dose-response relationship for consumers, or the effects of every commercial product formulation. 1 2 4

Approved-drug evidence is specific, not a claim about all CBD

In controlled trials involving Epidiolex for patients with Lennox-Gastaut syndrome or Dravet syndrome, common adverse reactions occurring in at least 10% of treated patients and more often than placebo included somnolence, decreased appetite, diarrhea, transaminase elevations, fatigue or malaise, rash, sleep-related problems, and infections. In a controlled tuberous-sclerosis-complex trial, commonly reported reactions included diarrhea, transaminase elevations, decreased appetite, somnolence, fever, and vomiting. 5

The same approved-drug evidence reported dose-related discontinuation patterns in the Lennox-Gastaut and Dravet syndrome trials: discontinuation for any adverse reaction occurred in 2.7% of patients receiving 10 milligrams per kilogram per day, 11.8% receiving 20 milligrams per kilogram per day, and 1.3% receiving placebo. Sedation, somnolence, or lethargy led to discontinuation in 3% of patients receiving 20 milligrams per kilogram per day, compared with 0% in the 10-milligram-per-kilogram-per-day and placebo groups. 5

The Epidiolex trials also reported weight decreases, anemia-related laboratory findings, and increases in serum creatinine; the creatinine increase was approximately 10% within two weeks in controlled studies of healthy adults and patients with the listed seizure disorders. These are findings from drug trials conducted in defined patient populations and dosing conditions. They do not show that consumer CBD products treat the same conditions or have the same composition, route, dose, monitoring, or risk profile. 5

The practical bottom line

THC: controlled human studies found acute intoxication, sedation, anxiety, dysphoria, positive psychotic symptoms, increased heart rate, driving impairment, and cognitive impairment under particular oral or vaporized conditions. 1 2 4

CBD alone: one controlled oral study found no difference from placebo on its measured symptomatic or physiological outcomes, while a vaporized CBD-dominant preparation did not significantly differ from placebo on lane weaving. Neither result establishes universal non-impairment. 1 4

CBD with THC: controlled studies produced mixed, outcome-specific findings. One found attenuation of selected psychotomimetic effects but not the THC-induced high; others found that CBD did not prevent THC-related driving or cognitive impairment, and one found some cognitive impairment was worse with equivalent THC and CBD. 2 3

CBD medicines: the supplied approved-drug evidence concerns Epidiolex trials for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. It supports conclusions about that medicine and those indications, not a universal therapeutic claim about CBD or consumer products. 5